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Abstract
Background: Mucosal melanomas are rare and aggressive neoplasms, with little published 
population-based data on predictors of survival.
Objective: To assess the influences of race/ethnicity, sex, tumor stage, tumor thickness, and 
anatomic site on mucosal melanoma survival estimates.
Methods: We analyzed 132,751 cases of melanoma, including 1,824 mucosal melanomas, 
diagnosed between 1994 and 2015 and reported to the California Cancer Registry. Kaplan-Meier 
survival analysis and Cox proportional hazards regression assessed the prognostic variables.
Results: The 5-year relative survival for mucosal melanomas (27.64%, 95% confidence interval 
[CI] 25.42 – 29.91) was significantly lower than for cutaneous melanomas (76.28%, 95% CI 76.03 
– 76.53). Stage independently influenced survival, and thickness did not predict survival for 
neoplasms of known depth. Less common anatomic sites conferred worse prognoses (hazard ratio 
[HR] 1.93, 95% CI: 1.41 – 2.64).
Limitations: Lack of a standardized staging system may have resulted in misclassification of 
stage for some neoplasms. The influence of genetics is unknown because our database did not 
contain genetic characteristics.
Conclusions: Stage and anatomic site, but not thickness (i.e. Breslow depth), race, or ethnicity, 
determine prognosis of mucosal melanomas. Considering the poor prognosis for all stages of 
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mucosal melanoma, dermatologists should incorporate examination of the oropharynx and 
genitalia in the full body skin exam.
CAPSULE SUMMARY
• This population-based study underscores that extracutaneous melanomas are rare and 
aggressive neoplasms. Poorer survival in patients with mucosal melanoma was 
observed in relation to stage and anatomic site, but not tumor thickness (i.e., Breslow 
depth) or patient race/ethnicity.
• Due to the poor prognosis for all stages of mucosal melanoma, dermatologists should 
consider incorporating examination of the oropharynx and genitalia in the full body 
skin exam.
Keywords
mucosal melanoma; survival; treatment; extracutaneous melanoma; epidemiology; population-
based; California Cancer Registry
INTRODUCTION
Accounting for approximately 1% of all melanomas,1–4 mucosal melanomas (i.e., 
extracutaneous melanomas) are rare and poorly characterized neoplasms that can be found 
on any mucosal surface. Due to their occult anatomical locations and lack of early 
presenting signs and symptoms, they are difficult to diagnose at an early stage, resulting in a 
poorer prognosis than cutaneous melanomas.3–6 Little evidence exists regarding predictors 
of survival from population-based survival data (i.e., data obtained from geographic or 
national registry databases), which are necessary for development of screening 
recommendations and targeted treatments.
Mucosal melanomas are pertinent to dermatologists because these neoplasms are often on 
the differential for pigmented lesions in sites that dermatologists examine on full body skin 
exams, including the oral mucosa and genitalia. The poor prognosis and lack of disease-
specific treatment guidelines or randomized controlled trials for mucosal melanomas 
requires extra attention.
Treatments for mucosal melanomas are often extrapolated from data based on therapies for 
metastatic cutaneous melanoma. However, while Breslow depth is a well-known predictor of 
survival in cutaneous melanomas, population-based multivariate analyses have yet to 
examine the effect of thickness on survival in mucosal melanomas. Although population-
based studies have shown that the five-year relative survival proportions of mucosal 
melanoma are poor compared with cutaneous melanoma4,7, of particular interest is how 
survival predictors differ between mucosal melanoma and cutaneous melanoma.
This study’s objective was to assess the independent influences of race/ethnicity, stage at 
diagnosis, and tumor thickness on mucosal melanoma survival, using a population-based 
database. While more detailed survival statistics on cutaneous melanoma exist elsewhere,8 
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we also included information on cutaneous melanomas for comparison with mucosal 
melanomas, as appropriate.
MATERIALS AND METHODS
Data source
Population-based melanoma incidence data were obtained from the California Cancer 
Registry (CCR: www.ccrcal.org), which comprises 10 regional registries. Patients selected 
for analysis were residents of California diagnosed with invasive melanoma between January 
1, 1994 and December 31, 2015 and reported to the CCR as of August 2016. Information 
regarding sex, race/ethnicity, tumor thickness, and other information were abstracted from 
the medical record within months after diagnosis.
Tumor Characteristics and Patient Demographics
We categorized melanomas into cutaneous and mucosal melanoma according to the methods 
of McLaughlin et al,1 excluding ocular melanoma for this analysis. Invasive tumors with 
histology codes 8720-8790 (International Classification of Diseases for Oncology, 3rd 
edition [ICD-O-3]) were selected for analysis (N=144,904).
Selected tumors were classified by their Breslow depth, anatomic site, and histologic type. 
Thickness was categorized in the same groups typically found in survival analyses (<1mm, 
1mm to <2mm, 2mm to <4mm, and 4mm or greater).
Anatomic site was identified from ICD-O-2 codes and classified according to the scheme 
used by McLaughlin et al.1 In the ICD-O-2 classification scheme, the skin of the anus and 
perianal skin are considered to be cutaneous. Cutaneous melanomas (ICD-O-2 code C44.0-
C44.9) excluded the skin of the vulva, penis, and scrotum, which are instead included with 
mucosal melanomas. Melanomas with unknown primary site were considered to be 
cutaneous.
We adopted the clinical and pathologic TNM staging system of the Surveillance, 
Epidemiology and End Results (SEER) program, distinguishing between localized (to the 
tumor boundary), regional (with lymph node or direct extension involvement only), and 
distant involvement.
Race/ethnicity was grouped into the mutually exclusive categories of Non-Hispanic Whites, 
Non-Hispanic Blacks, Hispanics, and Asian/Pacific Islanders, according to the race/ethnicity 
reported to the CCR. As done in other population-based studies on extracutaneous 
melanoma, Hispanic ethnicity was established using the North American Association of 
Central Cancer Registries Hispanic Identification Algorithm.9 Patients of any other race or 
unknown race and patients with unknown diagnosis or follow-up dates were removed from 
the study population, leaving 132,751 cases for analysis.
Statistical methods:
SAS Software 9.4 (SAS Institute Inc., Cary, NC) was used to perform survival analysis and 
multivariate regression. Survival time was measured as the number of months between 
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diagnosis and death. Patients still alive at last follow-up contributed their known survival 
time, but were censored from the analysis at the date of their last follow-up without an event 
(death). Survival curves and univariate descriptive statistics for survival by demographic and 
tumor characteristics were calculated using the Kaplan-Meier method. Because tumor 
thickness was unknown for over 70% of mucosal melanomas and tumor stage was missing 
for over 7% of mucosal melanomas, we included an “Unknown” group in all analyses 
involving tumor thickness or stage.
Cox proportional hazards regression was used to perform a multivariate analysis modeling 
survival on age, race/ethnicity, tumor thickness and stage at diagnosis, and primary tumor 
site for mucosal melanomas. For categorical variables including race, stage, thickness, and 
primary site, the selected reference groups were Non-Hispanic White, localized disease, <1 
mm thickness, and oral cavity, respectively. Associations with death from disease are 
presented in the results as hazard ratios with corresponding p-values.
RESULTS
Of the 132,751 diagnoses of melanoma registered in California between 1994 - 2015 and 
which included race/ethnicity data, 130,927 melanomas (98.6%) were cutaneous, and 1,824 
(1.4%) were mucosal. The five-year survival estimate for mucosal melanoma (27.64%, 95% 
confidence interval [CI] 25.42 – 29.91) was significantly lower than for cutaneous 
melanomas (76.28%, 95% CI 76.03 – 76.53).
Survival analysis by sex and race/ethnicity
Patients diagnosed with mucosal melanomas experienced lower five-year survival estimates, 
regardless of race/ethnicity or sex, than individuals diagnosed with cutaneous melanoma 
(Table 1, Figure 1). For cutaneous melanoma, females had statistically significantly better 
survival rates than men. Similarly, for mucosal melanoma, there was a survival advantage for 
females, with only slightly overlapping CIs.
While non-Hispanic whites had the best survival of all racial/ethnic groups for mucosal 
melanomas, the difference in rates was not statistically significant. For cutaneous 
melanomas, the five-year survival estimates for non-Hispanic whites, Hispanics, Asian/
Pacific Islanders, and non-Hispanic blacks were 76.57% (95% CI: 76.3 – 76.8), 73.96% 
(95% CI: 72.79 – 75.10), 66.53% (95% CI: 63.39 – 69.47), and 56.97% (95% CI: 51.99 – 
61.64), respectively.
Survival analysis by stage at diagnosis
Regardless of stage, mucosal melanomas had worse survival rates than similarly staged 
cutaneous melanomas (Table 2). Localized mucosal melanomas had worse survival rates 
than even regionally metastasized cutaneous melanomas (Figure 2).
Survival analysis by melanoma thickness
Mucosal melanomas of any thickness had worse survival estimates than cutaneous 
melanomas of any thickness, and cutaneous melanomas were more frequently thinner 
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tumors (Table 3). While survival decreased as cutaneous melanoma thickness increased, 
there was less prognostic value in tumor thickness for mucosal melanomas (Figure 3).
Survival analysis by anatomic site
When mucosal melanomas of known primary sites were categorized by primary anatomic 
site, their five-year survival estimates were 37.41% for genitourinary, 27.85% for oral cavity, 
23.77% for nasal and sinus, 20.94% for gastrointestinal, 16.68% for anorectal, and 13.57% 
for other sites (Table 3).
Multivariate analysis
After accounting for age, sex, race/ethnicity, and tumor stage at diagnosis, tumor thickness 
did not predict mucosal melanoma survival from tumors of known depth. The risk of death 
was increased for mucosal melanomas of unknown thickness (hazard ratio [HR] 1.47, 95% 
CI 1.15-1.89) (Table 4). Thickness was a statistically significant prognostic factor of death 
from cutaneous melanomas of all depths.
After controlling for the above factors in addition to thickness, stage at diagnosis was a 
statistically significant predictor of survival for both mucosal and cutaneous melanomas. For 
cutaneous melanoma, risk of death for distantly metastasized disease was almost eight times 
as high as for localized disease (HR 7.64, 95% CI 7.37 – 7.92). The effect was mirrored, 
although not to the same degree, for mucosal melanomas, as distantly metastasized mucosal 
melanomas increased risk of death by more than three times (HR 3.36, CI 2.9 – 3.92).
While race/ethnicity had minimal effect on death from cutaneous melanomas, with HRs 
ranging from 1.15-1.41, this factor did not affect risk of death for mucosal melanomas 
(Table 4). There remained a small a survival advantage for females with cutaneous 
melanoma (HR 0.75, 95% CI 0.74-0.77) and mucosal melanoma.
Mucosal melanomas from less common anatomic sites (e.g., spine/CNS, lung and pleura, 
liver and pancreas) conferred the worst prognosis (HR 1.93, 95% CI: 1.41 – 2.64). Oral, 
anorectal and gastrointestinal sites also negatively affected survival, with HRs of 1.37 (95% 
CI: 1.10 – 1.70) and 1.65 (95% CI: 1.19 – 2.27), respectively.
DISCUSSION
Due to the rarity of mucosal melanomas, few population-based studies have reported 
predictors of survival from these neoplasms. Our population-based analysis of survival 
outcomes over a 21-year time period found that stage at diagnosis is an independent risk 
factor for survival from mucosal melanoma, while tumor thickness and race/ethnicity are 
not. Consistent with previous population-based reports,1–4 we found that mucosal 
melanomas comprised approximately 1% of all melanomas. Our aggregate five-year survival 
estimate of approximately 28% was similar to a previously reported U.S. population-based 
estimate,10 thereby underscoring the current knowledge that mucosal melanoma continues to 
be an aggressive disease that carries a poor prognosis.
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Stage at diagnosis modified survival rates for cutaneous melanomas more than mucosal 
melanomas. This is likely because the risk of death from even a localized mucosal 
melanoma is even higher than for regionally metastatic cutaneous melanoma, possibly 
because these two types of melanomas are genetically distinct.11,12
While tumor thickness (i.e., Breslow depth) is the most important prognostic indicator for 
cutaneous melanomas,12 our results suggest that the same principle cannot be applied to 
mucosal melanomas. We found that tumor thickness conferred little prognostic value for 
survival from mucosal melanomas of known thicknesses, once stage was accounted for. 
Thickness likely had a smaller prognostic effect for mucosal melanomas because of their 
overall worse prognosis, compared to cutaneous melanomas. Notably, most (70%) of 
mucosal melanomas were of unknown depth, likely because they are difficult to detect and 
are likely to be metastatic at the time of diagnosis. Accordingly, the worst survival estimates 
were for patients with mucosal melanomas of unknown thickness. Thickness was not a 
predictor of survival for mucosal melanomas of known thickness and it could not be 
measured in a majority of mucosal melanomas, thus further reducing its utility as a basis for 
clinical decision-making for mucosal melanomas. The lack of difference in survival 
estimates between thin and thick mucosal melanomas suggests that even thin tumors should 
be aggressively treated with systemic therapy.
Consistent with previous population-based multivariate analyses,4 we found that race/
ethnicity is not an independent risk factor for mucosal melanoma survival. Regardless of 
race/ethnicity, patients with mucosal melanoma had worse prognoses than individuals 
diagnosed with cutaneous melanoma.
We showed that anatomic site influences survival, as mucosal melanomas in the most occult 
anatomic sites (e.g., spine/CNS, lung and pleura, liver and pancreas) had the worst 
prognosis, likely because they have already metastasized by the time they are diagnosed. 
Overall, our survival estimates based on anatomic site parallel the poor prognosis described 
in other population-based studies, which have provided five-year survival estimates ranging 
from 4% to 60%, depending on site.3,13 Although mucosal melanomas are infrequently 
encountered by dermatologists, they are often on the differential for pigmented mucosal 
lesions in sites that dermatologists can visualize, including the mouth and female genital 
tract. Currently, there are no mucosal melanoma consensus treatment guidelines or 
randomized controlled trials,14 and treatment regimens are often extrapolated from data 
based on therapies used to treat metastatic cutaneous melanoma.
In light of these findings, we recommend that dermatologists examine the oropharynx and 
the genitalia when performing a full body skin examination. The examination of the 
oropharynx includes asking the patient to lift up their upper lip, pull down their lower lip, 
and open their mouth so that the clinician can examine the palate. If a suspicious lesion in 
the oral mucosa is identified, we recommend referral to a dentist for biopsy and further 
evaluation. We also discuss with our patients that examination of the genital areas is 
recommended for full body skin exams, but patients can defer if they choose, or if they have 
regular follow-up with a gynecologist or urologist. These added steps are easy to incorporate 
into the full body skin examination and do not significantly prolong the encounter. Using 
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these methods, the authors have identified mucosal melanomas in the oral cavity and genital 
areas. Given the poor prognosis of mucosal melanomas, we recommend that dermatologists 
consider implementing a comprehensive method of performing full body skin exams.
Limitations include the lack of a standardized staging system for mucosal melanomas, which 
may have resulted in potential misclassification of the extent of spread of some mucosal 
melanomas. Because our database did not have data on the genetic characteristics of the 
cases or their tumors, it is difficult to determine whether these factors modify our 
observations. Despite the aforementioned limitations, this study has several strengths. Most 
importantly, we used a population-based dataset with a large enough sample size to explore 
relationships between multiple. Compared to data from a single clinical institution, in which 
patient participation could represent a biased selection of mucosal melanomas, our data from 
a population-based registry is more generalizable to the United States population.
In conclusion, this study of twenty-one years of population-based California Cancer 
Registry data demonstrated that mucosal melanoma continues to be an aggressive disease 
with a poor prognosis. We found that stage at diagnosis is an independent risk factor for 
survival from mucosal melanoma, but tumor thickness and race/ethnicity are not. 
Anatomical site affects survival from mucosal melanomas, with tumors of less common 
anatomic sites conferring the worst prognosis. Because of the poor prognosis for mucosal 
melanomas of all stages, clinicians should consider treating more aggressively at the time of 
diagnosis and advocating for development of treatments specific to mucosal melanoma.
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Figure 1. 
Survival for cutaneous and mucosal melanoma by sex and race/ethnicity in California. 
California Cancer Registry, 1994-2015. (a) Cutaneous versus mucosal melanoma survival by 
sex. (b) Cutaneous melanoma survival by race/ethnicity. (c) Mucosal melanoma survival by 
race/ethnicity.
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Figure 2. 
Survival for cutaneous and mucosal melanoma in California, by tumor stage at diagnosis. 
California Cancer Registry, 1994-2015
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Figure 3. 
Survival for cutaneous and mucosal melanomas in California, by tumor thickness and 
anatomic site. California Cancer Registry, 1994-2015. (a) Cutaneous versus mucosal 
melanoma survival by thickness. (b) Mucosal melanoma survival by thickness. (c) Mucosal 
melanoma survival by primary anatomic site.
Altieri et al. Page 11
J Am Acad Dermatol. Author manuscript; available in PMC 2020 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Altieri et al. Page 12
Table 1.
Cutaneous and mucosal melanomas by sex and race/ethnicity in California. California Cancer Registry, 
1994-2015
Cutaneous Mucosal
Cases 5-year Survival Estimate Cases 5-year Survival Estimate
N % Survival Estimate (%) 95% CI (%) N % Survival Estimate (%) 95% CI
Sex
Male 77,921 59.51% 72.20 71.86, 72.55 580 31.80% 23.20 19.53, 27.06
Female 53,006 40.49% 82.28 81.92, 82.63 1,244 68.20% 29.71 26.96, 32.50
Race/ethnicity
Non-Hispanic White 122,379 93.47% 76.57 76.31, 76.83 1,261 69.13% 28.48 25.82, 31.19
Non-Hispanic Black 470 0.36% 56.97 51.99, 61.64 53 2.91% 20.54 10.41, 33.05
Hispanic 6,924 5.29% 73.96 72.79, 75.10 310 17.00% 26.55 21.20, 32.18
Asian/Pacific Islander 1,154 0.88% 66.53 63.39, 69.47 200 10.96% 25.82 19.23, 32.90
Total Cases 130,927 1,824
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Table 2.
Survival for cutaneous and mucosal melanoma in California, by tumor stage at diagnosis. California Cancer 
Registry, 1994-2015
Cutaneous Mucosal
Cases 5-year Survival Estimate Cases 5-year Survival Estimate
N % Survival Estimate (%) 95% CI (%) N % Survival Estimate (%) 95% CI
Stage at Diagnosis
Localized 109,982 84.00% 82.87 82.62, 83.12 790 43.31% 43.93 40.13, 47.67
Regional 10,515 8.03% 50.58 49.52, 51.64 518 28.40% 18.76 15.20, 22.62
Remote 5,773 4.41% 13.50 12.54, 14.50 384 21.05% 7.84 5.13, 11.29
Unknown 4,657 3.56% 55.65 54.09, 57.19 132 7.24% 20.97 13.98, 28.93
Total Cases 130,927 1,824
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Table 3.
Survival for cutaneous and mucosal melanoma in California, by tumor thickness and primary site at diagnosis, 
California Cancer Registry, 1994-2015
Cutaneous Mucosal
Cases 5-year Survival Estimate Cases 5-year Survival Estimate
N % Survival Estimate (%) 95% CI N % Survival Estimate (%) 95% CI
Thickness at Diagnosis
Less than 1mm 74,885 57.20% 87.70 87.44, 87.96 161 8.83% 48.83 40.28, 56.82
1mm to <2mm 20,413 15.59% 77.38 76.74, 78.00 126 6.91% 51.94 41.83, 61.12
2mm to <4mm 11,777 9.00% 61.10 60.12, 62.06 98 5.37% 44.28 32.80, 55.14
4mm or greater 8,642 6.60% 43.10 41.94, 44.26 142 7.79% 29.01 20.62, 37.91
Unknown 15,210 11.62% 50.56 49.73, 51.40 1,297 71.11% 21.29 18.92, 23.75
Primary Site
Oral Cavity 174 9.54% 27.85 20.58, 35.57
Anorectal 358 19.63% 16.68 12.58, 21.28
Nasal and Sinus 452 24.78% 23.77 19.65, 28.13
Genitourinary 700 38.38% 37.41 33.53, 41.29
Gastrointestinal 68 3.73% 20.94 11.82, 31.84
Other 72 3.95% 13.57 6.32, 23.58
Total Cases 130,927 1,824
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Table 4.
Multivariate models predicting cutaneous and mucosal melanoma death in the population of California. 
California Cancer Registry, 1994-2015
Cutaneous (N=130,927) Mucosal (N = 1,824)
Hazard ratio 95% CI Hazard ratio 95% CI
Five-Year Age Group 1.33** 1.33, 1.34 1.12** 1.09, 1.14
Sex
 Male reference reference
 Female 0.75** 0.74, 0.77 0.92 0.81, 1.04
Race
 Non-Hispanic White reference reference
 Non-Hispanic Black 1.41** 1.24, 1.60 1.06 0.77, 1.44
 Hispanic 1.15** 1.10, 1.20 1.03 0.89, 1.20
 Asian/Pacific Islander 1.17* 1.07, 1.29 0.93 0.78, 1.11
Stage
 Localized reference reference
 Regional 1.96** 1.90, 2.02 1.76** 1.54, 2.02
 Distant 7.64** 7.37, 7.92 3.36** 2.90, 3.92
 Unknown 1.74** 1.66, 1.82 1.71** 1.38, 2.13
Thickness
 <1mm reference reference
 1mm - <2mm 1.47** 1.43, 1.51 0.93 0.68, 1.26
 2mm - <4mm 1.95** 1.89, 2.01 1.08 0.78, 1.51
 4mm or more 2.27** 2.19, 2.35 1.18 0.88, 1.58
 Unknown 1.92** 1.85, 1.98 1.47* 1.15, 1.89
Primary Site
 Oral Cavity reference
 Anorectal 1.37* 1.10, 1.69
 Nasal and Sinus 1.08 0.88, 1.33
 Genitourinary 1.20 0.96, 1.50
 Gastrointestinal 1.65* 1.19, 2.27
 Other 1.93** 1.42, 2.64
Covariates include age, sex, race/ethnicity, tumor stage at diagnosis, tumor thickness at diagnosis, and mucosal primary site. Significance is 
indicated as follows:
*p<0.01,
**p<0.0001
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